Furthermore, these findings of ARK1B10 in the Cx43 secretome also open the possibility of gliomas utilizing Cx43 to not only increase migration but additionally set up ECM defenses to inactivate therapeutic agents prior to their arrival at gliomas. This evidence concerns the gene GJA1 and glioma.